Publications & Posters

Publication

Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine

https://doi.org/10.1016/j.leukres.2022.106884
Publication

Inhibition of Bromodomain and Extra Terminal (BET) Domain Activity Modulates the IL-23R/IL-17 Axis and Suppresses Acute Graft- Versus-Host Disease

https://doi.org/10.3389/fonc.2021.760789
Poster

Phase 1b/2a Study of PLX2853, a Small Molecule BET Inhibitor, in Subjects with Advanced Solid Tumors and Lymphoma

  • AUTHORS Gordon, et al
  • Programs OPN-2853
Download PDF
Publication

A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia

https://doi.org/10.3324/haematol.2020.247346
Poster

Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Download PDF
Publication

BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression

https://doi.org/10.1182/bloodadvances.2020002231
Publication

Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanoma

https://doi.org/10.1038/s41416-019-0724-y
Poster

Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

  • AUTHORS Pemmaraju, et al
  • Programs OPN-2853
Download PDF
Publication

PLX3397 inhibits the accumulation of intra-tumoral macrophages and improves bromodomain and extra-terminal inhibitor efficacy in melanoma

https://doi.org/10.1111/pcmr.12845
Publication

Potentiated anti-tumor effects of BETi by MEKi in anaplastic thyroid cancer

https://doi.org/10.1530/ERC-19-0107